Title

Factors affecting anal sphincter recruitment during intraoperative pudendal nerve stimulation

Authors

Amador C Lagunas[1,2], Po-Ju Chen[1,2], Luis Ruiz[1,2], Amolak S Jhand[1,2], Nystha Baishya[1,2], Scott F Lempka[1,2,3], Priyanka Gupta[4], Tim M Bruns[1,2]

Affiliations

[1]Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA

[2]Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA

[3]Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA

[4]Department of Urology, University of Michigan, Ann Arbor, MI, USA

Acknowledgments

Thank you to Dr. Gaurang Shah (radiology), Vanessa Pruitt (study coordinator), and Mackenzie Moore (study coordinator). We also thank Kelly Ridenour and Stephanie Jones from the Michigan Medicine Neurology Intraoperative Neural Monitoring team for their EMG identification expertise and data collection support.

Data availability statement

The data set from the study will be found on the SPARC Science data portal at DOI: 10.26275.pc8r-r3iu after completing the SPARC curation process.

Funding statement

This project was funded through the NIH SPARC program (award OT2OD028191).

Clinical trial registration

This study was registered at clinicaltrials.gov (NCT04236596).

Abstract

Introduction: The factors that impact external anal sphincter (EAS) recruitment in clinical pudendal neuromodulation are not well understood. Therefore, the goal of this study was to identify and quantify physiological, demographic, and stimulation factors that significantly affect EAS recruitment in participants receiving pudendal neuromodulation for treatment of lower urinary tract symptoms.

Methods: Demographic and diagnostic information were collected from participants upon entry to the study. MRI and CT were used to capture patient pudendal nerve anatomy and register the location of the implanted lead. EAS activation by pudendal nerve stimulation at different amplitudes and pulse widths was recorded during neurostimulator lead implantation in the operating room. Linear mixed modeling was used to quantify the impact each variable had on EAS recruitment in the sixteen enrolled participants.

Results: Participant sex, age, and BMI did not significantly affect EAS recruitment with pudendal nerve stimulation. Participant diagnoses had significant relationships to EAS recruitment, likely due to unbalanced group sizes. A pulse width of 210 µs required significantly less current than 60 µs (p = 0.005) to activate the EAS at threshold and significantly less charge than 450 µs (p = 0.02) to activate the EAS at threshold. Increased distance between the stimulating electrode and the pudendal nerve decreased the magnitude of the EAS response (p = 0.0011) and increased EAS activation threshold (p < 0.001).

Conclusions: Of the three tested pulse widths, 210 µs requires the least charge and is a good choice for stimulation. The distance between the electrode and pudendal nerve plays an important role in EAS and pudendal nerve recruitment and minimizing this distance should be a priority during lead implantation.

Keywords

pudendal nerve, neuromodulation, linear mixed model, electromyography, external anal sphincter

Introduction

Chronic pelvic pain and lower urinary tract disorders (LUTD) are serious medical conditions that affect millions of people globally[1–3]. Pelvic pain is a complex condition with possible causes ranging from damage to inflammation and can be felt throughout the pelvis in the internal organs or genitalia. These conditions negatively impact quality of life as they can result in diminished physical health, mental health, and productivity[4–6]. LUTD can develop at any age[6,7] and will become more prevalent as the population continues to age[8]. Generally, behavioral changes and pharmaceutical management are standard first- and second-line treatments for pelvic pain and LUTD.

Neuromodulation, or nerve electrical stimulation, is a third line treatment for people with LUTD, such as overactive bladder, who have failed to respond to more conservative treatments[9]. Pudendal neuromodulation has emerged as an off-label treatment for overactive bladder and chronic pain[10,11]. The pudendal nerve is a mixed nerve that innervates the pelvic floor muscles, external anal sphincter, and external urethral sphincter and is involved in reflex circuits that control urine storage and micturition[12]. Early neuromodulation studies used pudendal nerve stimulation to determine if patients would respond to sacral neuromodulation[13,14] as the pudendal nerve is composed of fibers that pass through the S2-S4 roots[12]. Chronic pudendal neuromodulation has been used as treatment for individuals who fail to respond to sacral neuromodulation[15,16].

While pudendal neuromodulation can relieve symptoms associated with overactive bladder and chronic pelvic pain, the degree of benefit can vary widely between patients and diminish over time[11,17]. In one pilot study, 16% (3/19) of participants had the device explanted after 2.95 years due to loss of efficacy[17]. With few clinical studies investigating the long-term success of pudendal neuromodulation[11,17–20], there is not a thorough understanding of what causes this inconsistency in treatment outcomes.

Typically, the neurostimulator implant procedure involves two surgical stages. In the stage-1 implant surgery, the stimulation lead is placed near the main trunk of the pudendal nerve. After a 2-to-3-week evaluation period, if patient symptoms have improved the pulse generator is placed in the lower back and connected to the lead in a stage-2 procedure. Anal sphincter recruitment in response to pudendal stimulation during the stage-1 surgery is a key indicator that the lead is correctly positioned and recruiting fibers in the main trunk of the pudendal nerve[15]. However, to our knowledge, no previous study has investigated what factors influence recruitment of the anal sphincter. Therefore, the goal of this study was

to determine which stimulation parameters and physiological factors have a significant impact on the recruitment of the inferior rectal branch of the pudendal nerve during pudendal nerve stimulation. To achieve this goal, anal sphincter EMG responses were collected during the stage-1 lead implant surgery. Participant age, sex, and BMI data were collected as well. Additionally, volumetric imaging was conducted for each participant and patient specific segmentations of the pelvic anatomy and implanted lead were created. The segmentations were used to investigate the impact that pudendal nerve to electrode distance had on anal sphincter recruitment.

Overall, we found that while a longer stimulation pulse width generally increased inferior rectal branch recruitment, a 210-microsecond pulse width required the lowest combined current and charge for anal sphincter activation. We also successfully demonstrated that the distance between the implanted electrode and the pudendal nerve varied across participants and that larger distances decreased EAS recruitment.

Materials and Methods

We recruited patients who were scheduled to undergo pudendal neuromodulation for the treatment of voiding dysfunction and/or pelvic pain. This was a single center study with all surgeries performed by the same physician. After providing informed consent, participants had a pelvic magnetic resonance imaging (MRI) scan, stage-1 implant surgery, and a postoperative pelvic X-ray computed tomography scan. Participants could withdraw from the study at any time. People were excluded from the study if they were pregnant or planned to be pregnant during the study or had a neurogenic bladder. Premenopausal women underwent a urine pregnancy test prior to the preoperative MRI scan.

Operating room setup

Data was collected during the stage-1 surgery, in which an Interstim (Medtronic, MN, USA) electrode lead was inserted near the pudendal nerve, as described in Peters 2013[21]. To summarize, the patient was placed prone under anesthesia in a sterile field. Monopolar needle electromyography (EMG) electrodes (Ambu, MD, USA), were placed in the external anal sphincter at the 3 and 9 o'clock positions. The needle electrodes were connected to a Cascade Elite (Cadwell, WA, USA) intraoperative neurophysiological monitor on which the external anal sphincter (EAS) EMG data was displayed live and recorded with a 333 hertz (Hz) sampling rate. The EMG data was filtered by the Cascade system with 3 kHz low pass and 10 Hz high pass filters, and a 60 Hz filter when 60 Hz noise was observable.

A foramen needle was inserted through the skin toward the ischial spine. The position of the foramen needle was adjusted while delivering stimulation until compound motor action potentials were seen on the anal sphincter EMG. The foramen needle was then replaced with a tined quadripolar lead. Each electrode on the lead was stimulated to check for anal sphincter compound motor action potentials on the EMG. Once the lead position was deemed satisfactory, brief stimulation trials were performed for this study.

Study data collection

To assess the effects of different stimulation parameters on anal sphincter recruitment, we conducted trials with varying stimulation amplitudes, pulse widths, and electrode combinations while recording the resulting anal sphincter response with EMG. The implanted lead had four electrodes that could be activated individually (monopolar referenced to a surface electrode on the ankle) or used in any bipolar combination once the external pulse generator was connected. Stimulation was performed at either 3 Hz

for monopolar stimulation or 3.1 Hz for multipolar stimulation due to device constraints. This stimulation frequency was used so each muscle contraction could be identified clearly and without interruption from the following stimulation-driven contraction. Each trial was at least 10 seconds long. Three different pulse widths were used: 60, 210, and 450 μs. Typically, a 210 μs pulse width is used clinically, and 60 and 450 μs represent the smallest and largest pulse width the neurostimulator can generate.

For a given electrode and pulse width combination, the lowest stimulation amplitude that elicited an observed anal sphincter contraction was called the threshold amplitude. Experimental trials were performed at and above the threshold amplitude to a maximum of 5.5 mA or 5.5 V, depending on the pulse generator model. In most cases, monopolar trials were performed for all three pulse widths using electrodes that elicited an anal sphincter response until the next stage of the surgery was to begin. Charge per pulse was calculated by multiplying the set applied current by the pulse width for a given trial.

Patient specific calculation of electrode-to-nerve distance

We used volumetric imaging to create patient-specific three-dimensional models of the pelvic anatomy and measured the distances between the pudendal nerve and individual electrodes on the implanted lead. Before the stage-1 surgery, participants had a series of 3T T2 weighted MRI scans taken of their pelvis with an Ingenia 3T system (Philips, Amsterdam, the Netherlands) to enable identification and segmentation of pelvic viscera and nerves. The Mimics Research Version 25.0 (Materialise, Leuven, Belgium) and the Vascular Modeling Toolkit (v1.4.0; http://www.vmtk.org/) was used to segment the pudendal nerve. After implantation of the lead, participants had a helical CT scan with a Discover CT750 HD or Revolution scanner (GE Healthcare, IL, USA), depending on availability, from the L4 vertebra to the proximal femur shaft with a slice thickness of 0.625 mm. We segmented the CT scan using the Mimics Innovation Suite, identifying the implanted lead artifacts and bony structures, and co-registered surface segmentations derived from the MRI and CT scans to align the lead and nerve. The lead geometry was recreated from the CT artifacts using the geometry functions of Comsol Multiphysics Version 5.6 (Comsol, Stockholm, Sweden). The distance from each electrode on the lead to the closest part of the pudendal nerve was measured based on their center-to-center distance. If the lead had shifted by more than five millimeters from the stage-1 implant to the CT imaging, based on intraoperative fluoroscopy images taken of the coronal and sagittal planes, then data from that participant was not used when characterizing how the electrode-to-nerve distance affected the stimulation outcomes.

Data Analysis

EMG quantification was conducted in MATLAB (version 2021a, MathWorks, Natick, Massachusetts, USA). For each trial, we calculated the average area under the curve (AUC) EAS EMG for five stimulation events (Figure 1). This value was used to quantify the magnitude of the anal sphincter contraction, as done previously [22–24], and to represent EAS activation. The EAS EMG was rectified, and five stimulation events were averaged. The AUC calculation interval started 10 milliseconds after the stimulation artifact onset and continued for 100 milliseconds.

We used a Shapiro-Wilk test to check if each data set was normally distributed. Most of the data sets were found to be non-normally distributed, so a Kruskal-Wallis test was used to determine if groups had equal medians. This was followed by a pairwise Mann-Whitney U test with a Bonferroni correction as a post hoc test to determine which groups had statistically significant differences after a rejection of the null hypothesis with a Kruskal-Wallis test. Finally, a Mann-Whitney test was applied to compare the medians

between two non-normal data sets. Where relevant, values are given for the median and interquartile range (IQR) or average and standard deviation. A significance level of α = 0.05 was used.

Linear regression was used to examine the relationship between continuous variables. This dataset represented a multilevel model as trials coming from the same participant were not independent and the participants represented a sample of the patient population. Linear mixed models were used to estimate the AUC and the current required at threshold. Participant age, sex, body mass index (BMI), lower urinary tract symptoms (overactive bladder, urinary retention, urinary incontinence, and pelvic pain), and stimulation parameters (stimulation current, pulse width, electrode-to-nerve distance) were used as covariates in the model. R Statistical Software (v4.2.2; R Core Team 2023) was used to conduct statistical analysis. We used the R packages *lme4* and *lmerTest* to calculate the linear mixed model parameters. ANOVA was used to compare models and determine which fixed effects to include. Participants were classified as having OAB, retention, incontinence, or pelvic pain based on the diagnoses given by their examining urologist. Diagnoses of urge urinary incontinence, stress urinary incontinence, or mixed urinary incontinence were all classified as incontinence. Diagnoses of pelvic pain, pudendal neuralgia, vulvodynia, and interstitial cystitis were all classified as pelvic pain in the statistical analysis.

Results

We collected data from sixteen participants (3 male, 13 female) in this study. Participant 1017 had their implanted lead removed after damage and was re-enrolled as participant 1021. Patient information is summarized in Table 1. Most participants had issues with pelvic pain and either retention or overactive bladder as a comorbidity. Eight participants who were recruited into the study did not complete intraoperative data collection because of issues with insurance approval, unsuccessful device implantation, or study withdrawal before data collection and were not included in this analysis.

Pudendal nerve stimulation thresholds across participants

The distribution of threshold current levels for monopolar and bipolar stimulation was non-normal (p < 0.001). The monopolar anal sphincter activation threshold was relatively low across participants, at a median stimulation current of 1.90 (IQR = 1.2), 0.75 (0.45), and 0.55 (0.45) mA for 60, 210, and 450 μs pulse widths, respectively. The median threshold current levels for the three pulse widths were not the same (p = 0.001), and 60-μs data differed significantly from 210 μs (p = 0.005) and 450 μs (p = 0.004) data (Figure 2B).

The median bipolar threshold with a 210 μs pulse width was 0.75 mA (IQR = 0.65). There was no significant difference between monopolar and bipolar thresholds (p = 0.98) (Figure 2D). Participants 1014, 1016, 1017, and 1021 were not included in this analysis as their devices were voltage controlled.

The charge at EAS threshold was not normally distributed (p < 0.001). The median charge required for 60, 210, and 450 μs pulse widths was 114.0 (IQR = 72.0), 157.5 (94.5), and 247.5 (202.5) nC, respectively. These three groups did not have the same median (p = 0.001). There was a significant difference between the median charge required at anal sphincter threshold for 450 and 210 μs pulse widths (p = 0.02) and 450 and 60 μs pulse widths (p = 0.004) (Figure 3B).

Linear regression model with all monopolar trials

The first linear mixed model estimated AUC with patient demographics, participant diagnoses, and monopolar stimulation parameters as variables. The estimate for each statistically significant fixed effect

is given in Table 2. A representative equation for the corresponding linear model is shown in equation S1. Patient demographic data (BMI, age, or sex) did not have a significant fixed effect. Current and pulse width significantly affected EAS AUC amplitude. Diagnoses of OAB (n=12) or retention (n=5) had significant effects on the estimate of EAS AUC but diagnoses of urinary incontinence (n=7) or pelvic pain (n=12) did not. This observed effect is due to the unbalanced group sizes, as only one participant did not have either condition and their mean AUC values were larger than the average for all other study participants. The EAS AUC for each diagnosed condition is shown in Figure S1. Figures S1A and S2B show the relative imbalance in OAB and retention condition group sizes visually. Overall, we included 343 monopolar trials across sixteen participants in this model. The relationship between EAS response and applied current across pulse widths can be seen in Figure S2.

Linear regression models incorporating electrode-to-nerve distance

Five participants had reliable measurements of the distance between the electrodes on the implanted lead and the pudendal nerve. The distance between the nerve and the electrode for each participant is shown in Figure 4.

A second linear mixed model was created using data from the participants with reliable measurements, incorporating the applied current, pulse width, and electrode-to-nerve distance for each trial to determine the effect on EAS AUC. No participant level covariates were included in this model. Electrode-to-nerve distance, stimulation current, and pulse width were all significant fixed effects on the anal sphincter amplitude. Table 3 shows the fixed effect estimate for each significant fixed factor. There were no significant random effects. Participant ID was used as the grouping factor. A representative equation for the corresponding linear model is shown in equation S2.

A third linear mixed model was created to evaluate the impact of electrode-to-nerve distance and stimulation pulse width on the required current at threshold EAS recruitment. The results are given in Table 4. Electrode-to-nerve distance significantly increased the EAS recruitment current threshold. Pulse widths of 210 µs and 450 µs both lowered the expected threshold value as compared to 60 µs. A representative equation for the corresponding linear model is shown in equation S3.

Discussion

In this study, we examined the influence of patient demographic data, diagnosed pelvic conditions, and stimulation parameters on anal sphincter recruitment during pudendal nerve stimulation. To our knowledge, we believe that this is the first study which investigates the aforementioned relationships in human subjects. We showed that stimulation pulse width plays a significant role in anal sphincter recruitment and that an intermediate pulse width of 210 µs has a balance between EAS recruitment and applied current. Following this, we also calculated the distance between each electrode on the implanted lead and the pudendal nerve in a subset of participants and used a linear mixed model to investigate how electrode-to-nerve distance impacts anal sphincter recruitment. We demonstrated that electrode-to-nerve distance has a significant effect on anal sphincter recruitment and threshold current.

We saw that pulse widths of 210 µs and 450 µs have a significantly lower EAS activation threshold current than a pulse width of 60 µs (Figure 2B). However, activating the EAS at threshold requires less charge with a pulse width of 210 µs and 60 µs than 450 µs (Figure 3B). This data shows that an intermediate pulse width around 210 µs balances the minimum required current and charge and therefore requires the least amount

of energy to activate the anal sphincter, as compared to the other pulse widths we evaluated. These results agree with the findings of an earlier study[25] and support the use of common sacral neuromodulation pulse width parameters in pudendal neuromodulation.

Results from the linear mixed model show that pulse width significantly affects EAS recruitment across all current levels (Table 2, Table 3). When the pulse width was changed from 60 to 210 or 450 µs, while keeping every other variable the same, the mean magnitude of EAS response increased by 1.91 µV*s or 2.38 µV*s, respectively (Table 2). This trend suggests that changing pulse width not only affects the EAS recruitment at threshold, as shown in Figure 2B, but also at higher current levels.

In our dataset, no patient demographic data had a significant effect on anal sphincter recruitment. However, participants with overactive bladder or retention had a mean reduction of the EAS AUC when compared to the estimate for stimulation, based on 95% confidence interval testing (Table 2). If true, these results would suggest that people with these diagnoses might require more current than is typical to activate the EAS and recruit the pudendal nerve. However, it is important to note that there were uneven sample sizes in our study population and diagnoses of neither OAB nor retention (n=2) or both (n=1) were rare. The mixed model estimates had large errors, 0.58 and 0.57 for OAB and retention, respectively, showing that the strength of the effect varied across participants. Future studies should examine the relationship between a diagnosis of OAB or retention and EAS recruitment.

When looking at the relationship between pulse width, current, and electrode-to-nerve distance, the results from the linear mixed model (Table 3) show that they all significantly impacted EAS recruitment. As we might predict, increasing the distance between the nerve and the electrode reduced the magnitude of the EAS response. As Figure 4 shows, most participants had the closest electrode approximately 5 mm away. However, this minimal electrode-to-nerve distance can vary across participants. Larger distances between the nerve and electrode required more current for EAS activation and pudendal nerve recruitment. This relationship also held true when looking at the current required to activate the EAS at threshold. Table 4 shows that when the nerve and electrode are further away from one another the threshold current increased. Together, this data shows the importance of minimizing the electrode-to-nerve distance in pudendal neuromodulation.

Generally, the goal when implanting a pudendal stimulation lead is to activate the anal sphincter with a current below 2 mA[26] with at least three electrodes[27]. In this study, 94% (15/16) of participants had EAS activation below 2 mA with a 210 µs pulse width (Figure 2A). While lead implantation at the pudendal nerve is a challenging procedure, these results show that pudendal nerve stimulation can consistently activate the EAS at low current when the lead is placed by an experienced surgeon.

During the implant surgery, monopolar stimulation is used to locate the nerve and adjust the position of the foramen needle or lead. However, most pudendal neuromodulation patients use bipolar electrode combinations to manage their symptoms at home. In our data, we did not see a significant difference in the threshold current for monopolar trials and bipolar trials (Figure 2D). Therefore, our results support the continued use of monopolar stimulation to confirm intraoperative lead location.

Evoked EAS responses due to stimulation were monitored live and identified manually, leaving room for human judgement errors. Therefore, the measured threshold current could be misidentified. However, the threshold current is typically unambiguous and even if it were incorrectly labelled with an error ~0.1 mA the effect on the results would be minimal. The relative depth of the EAS needles was not tracked across

procedures. In general, the surgeon seeks to place the needles as deep as possible with a consistent position on opposite sides of the sphincter, however it is possible one or both needles shift during a surgical procedure which could affect the EMG recording.

There is an unbalanced grouping in the number of participants with OAB and the gender ratio of participants with OAB that limits the conclusions we can make in this study. Additional studies should be done with larger samples sizes and balanced diagnoses to investigate the relationship between EAS recruitment and OAB diagnosis.

Conclusion

A 210 µs pulse width is commonly used during pudendal neuromodulation[25], but this value has not been clearly justified in humans with current stimulation technologies. This study highlights the benefits of a 210 µs stimulation pulse width, as compared to 60 and 450 µs, and provides support for its continued use in pudendal neuromodulation. Overall, pudendal nerve stimulation is effective at activating the pudendal nerve and EAS in patients with a wide range of LUT symptoms and backgrounds. Minimizing the distance between the nerve and electrode is critical for recruitment of the pudendal nerve. Larger distances require more current to activate the nerve and therefore reduce the battery lifespan of implanted devices and reduce the size of the therapeutic window. Future studies should examine how bipolar stimulation affects pudendal nerve recruitment at different distances from nerve to electrode and look deeper at how LUT dysfunction may affect recruitment of the EAS with pudendal nerve stimulation.

References

1. Stewart W, Van Rooyen J, Cundiff G, et al. Prevalence and burden of overactive bladder in the United States. *World J Urol*. 2003;20(6):327-336. doi:10.1007/s00345-002-0301-4
2. Latthe P, Latthe M, Say L, Gülmezoglu M, Khan KS. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. *BMC Public Health*. 2006;6(1):177. doi:10.1186/1471-2458-6-177
3. Mckellar K, Bellin E, Schoenbaum E, Abraham N. Prevalence, Risk Factors, and Treatment for Overactive Bladder in a Racially Diverse Population. *Urology*. 2019;126:70-75. doi:10.1016/j.urology.2018.12.021
4. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. *BJU Int*. 2006;97(1):96-100. doi:10.1111/j.1464-410X.2005.05889.x
5. Coyne KS, Wein AJ, Tubaro A, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. *BJU Int*. 2009;103:4-11. doi:10.1111/j.1464-410X.2009.08371.x
6. Eapen R, Radomski S. Review of the epidemiology of overactive bladder. *Res Rep Urol*. 2016;8:71-76. doi:10.2147/RRU.S102441
7. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five Countries: Results of the EPIC Study. *Eur Urol*. 2006;50(6):1306-1315. doi:10.1016/j.eururo.2006.09.019
8. Puckrein G, Walker D, Xu L, Congdon P, Gooch K. The prevalence and forecast prevalence of overactive bladder in the medicare population. *Clin Med Insights Urol*. 2019;12. doi:10.1177/1179561119847464
9. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. *J Urology*. 2012;188(6S):2455-2463. doi:10.1016/j.juro.2012.09.079

10. Peters KM, Killinger KA, Boguslawski BM, Boura JA. Chronic pudendal neuromodulation: Expanding available treatment options for refractory urologic symptoms: Chronic Pudendal Neuromodulation. *Neurourol Urodyn*. 2010;29(7):1267-1271. doi:10.1002/nau.20823

11. Jottard K, Bruyninx L, Bonnet P, Mathieu N, De Wachter S. Pilot study: pudendal neuromodulation combined with pudendal nerve release in case of chronic perineal pain syndrome. The ENTRAMI technique: early results. *Int Urogynecology J*. 2021;32(10):2765-2770. doi:10.1007/s00192-020-04565-1

12. de Groat WC, Yoshimura N. Anatomy and physiology of the lower urinary tract. In: *Handbook of Clinical Neurology*. Vol 130. Elsevier; 2015:61-108. doi:10.1016/B978-0-444-63247-0.00005-5

13. Tanagho EA. Neuromodulation in the management of voiding dysfunction in children. *J Urol*. 1992;148(2 Part 2):655-657. doi:10.1016/S0022-5347(17)36684-3

14. Spinelli M, Malaguti S, Giardiello G, Lazzeri M, Tarantola J, Hombergh UVD. A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: Description of the method and preliminary data. *Neurourol Urodyn*. 2005;24(4):305-309. doi:10.1002/nau.20118

15. Peters KM, Feber KM, Bennett RC. Sacral versus pudendal nerve stimulation for voiding dysfunction: A prospective, single-blinded, randomized, crossover trial. *Neurourol Urodyn*. 2005;24(7):643-647. doi:10.1002/nau.20174

16. Gracely A, Gupta P. Pudendal neuromodulation for pelvic pain. *Curr Bladder Dysfunct Rep*. 2020;15(3):113-120. doi:10.1007/s11884-020-00588-y

17. Peters KM, Killinger KA, Jaeger C, Chen C. Pilot study exploring chronic pudendal neuromodulation as a treatment option for pain associated with pudendal neuralgia: neuromodulation and pudendal neuralgia. *LUTS Low Urin Tract Symptoms*. 2015;7(3):138-142. doi:10.1111/luts.12066

18. Heinze K, Hoermann R, Fritsch H, Dermietzel R, van Ophoven A. Comparative pilot study of implantation techniques for pudendal neuromodulation: technical and clinical outcome in first 20 patients with chronic pelvic pain. *World J Urol*. 2015;33(2):289-294. doi:10.1007/s00345-014-1304-7

19. Meier KM, Vecellio PM, Killinger KA, Boura JA, Peters KM. Pudendal neuromodulation is feasible and effective after pudendal nerve entrapment surgery. *J Sex Med*. 2022;19(6):995-1001. doi:10.1016/j.jsxm.2022.03.219

20. Hoang Roberts L, Vollstedt A, Volin J, McCartney T, Peters KM. Initial experience using a novel nerve stimulator for the management of pudendal neuralgia. *Neurourol Urodyn*. 2021;40(6):1670-1677. doi:10.1002/nau.24735

21. Peters KM. Pudendal neuromodulation for sexual dysfunction. *J Sex Med*. 2013;10(4):908-911. doi:10.1111/jsm.12138

22. Gregory WT, Lou JS, Stuyvesant A, Clark AL. Quantitative electromyography of the anal sphincter after uncomplicated vaginal delivery: *Obstet Gynecol*. 2004;104(2):327-335. doi:10.1097/01.AOG.0000134527.07034.81

23. Stålberg E, van Dijk H, Falck B, et al. Standards for quantification of EMG and neurography. *Clin Neurophysiol*. 2019;130(9):1688-1729. doi:10.1016/j.clinph.2019.05.008

24. Su X, Cutinella M, Koppes S, Agran JE, Dinsmoor DA. Electromyographic responses across different pulse-widths of sacral neuromodulation in sheep. *Neuromodulation Technol Neural Interface*. 2019;22(6):684-689. doi:10.1111/ner.12779

25. Plevnik S, Vodušek DB, Vrtačnik P, Janež J. Optimization of pulse duration for electrical stimulation in treatment of urinary incontinence. *World J Urol*. 1986;4(1):22-23. doi:10.1007/BF00326736

26. Vodušek DB, Plevnik S, Vrtačnik P, Janež J. Detrusor inhibition on selective pudendal nerve stimulation in the perineum. *Neurourol Urodyn*. 1987;6(5):389-393. doi:10.1002/nau.1930060506

27. Gilleran JP, Alpert SA, eds. *Adult and Pediatric Neuromodulation*. Springer International Publishing; 2018. doi:10.1007/978-3-319-73266-4

Tables

Table 1: Participant characteristics. Average and (standard deviation) given when relevant.

Variable	Count
Sex	
Female	13
Male	3
Diagnosed Condition	
Overactive Bladder	12
Retention	5
Incontinence	7
Pelvic Pain	12
Age (years)	55.9 (10.8)
BMI (kg/m^2)	28.4 (3.8)

Table 2: Summary of the significant fixed effects for the linear mixed model estimating AUC based on all monopolar trials.

Fixed Effect	Estimate (µV*s)	Standard Error	95% Confidence Interval	P value
Intercept	2.73	0.69	(1.44, 4.03)	4.67e-4
Current	0.79	0.10	(0.59, 0.98)	1.5e-14
Pulse Width 210 µs	1.91	0.35	(1.22, 2.59)	8.27e-8
Pulse Width 450 µs	2.38	0.39	(1.58, 3.13)	4.22e-9
OAB yes	-2.79	0.58	(-3.87, -1.71)	2.66e-4
Retention yes	-2.28	0.56	(-3.34, -1.22)	8.94e-4

Table 3: Summary of the significant fixed effects for the linear mixed model estimating AUC based on all monopolar trials with electrode-to-nerve distance data.

Fixed Effect	Estimate (µV*s)	Standard Error	95% Confidence Interval	P value
Intercept	0.76	0.73	(-0.63, 2.13)	0.32
Current	0.90	0.15	(0.59, 1.19)	7.3e-8
Pulse Width 210 µs	2.69	0.50	(1.72, 3.66)	5.6e-7
Pulse Width 450 µs	2.60	0.57	(1.44, 3.67)	2.2e-5
Distance	-0.27	0.07	(-0.41, -0.13)	1.1e-3

Table 4: Summary of the significant fixed effects for a linear mixed model estimating EAS threshold based on all monopolar trials with electrode-to-nerve distance data.

Fixed Effect	Estimate (mA)	Standard Error	95% Confidence Interval	P value
Intercept	0.78	0.35	(0.13, 1.44)	0.030
Pulse Width 210 μs	-0.86	0.32	(-1.47, -0.25)	0.011
Pulse Width 450 μs	-1.47	0.36	(-2.16, -0.79)	2.8e-4
Distance	0.22	0.03	(0.16, 0.28)	2.7e-7

Figures

Figure 1. Anal sphincter EMG and AUC Quantification. (A) Example EAS EMG after signal filtering showing five responses during a single trial. (B) Rectified and averaged example EMG signal (black) with individual traces (grey). (C) The AUC is represented by the shaded area under the rectified average EMG trace, between the vertical dashed lines.

Figure 2: Anal sphincter EMG activation thresholds for pudendal nerve stimulation per participant depending on stimulation (A), (B) pulse width for monopolar trials and (C), (D) polarity for 210 µs pulse width trials. Box plots in (B) and (D) represent the IQR for the height of each box, with the bold central line indicating the median. Tips of whiskers extend to the value(s) within 1.5 x IQR of each box side. ** indicates p < 0.01.

Figure 3: Charge per pulse at EAS activation threshold across pulse width for monopolar trials (A) per participant and (B) for all participants. Box plots are organized as in Figure 2. * Indicates p < 0.05, ** indicates p < 0.01.

Figure 4: The center-to-center distance between each electrode on the implanted quadripolar lead and the closest point on the pudendal nerve for study participants with lead migration less than 5 mm.